Our team

We are a comprehensive mix of experienced scientists and entrepreneurs. Our team brings together expertise in medical sciences, artificial intelligence and different life sciences industries.

Who are we?

ic_save time

100+ years

Our software team together holds over a century of experience in AI development

ic_be agile

80%

Over 80% of the Aiforia team have degrees in medical sciences or software development

ic_collaborate remotly

4 locations

Finland, United States, the Netherlands, United Kingdom

ic_aiforia create-1

15+ annotators

We have an in-house annotation team supporting all AI projects

Leadership Team

Jukka Tapaninen CEO

Jukka is the CEO of Aiforia and prior to joining the company he held various executive positions over the past 25 years in international IT and software businesses such as at SAP and HP. Some of the wealth of experience includes: leading enterprise software sales for healthcare industries as well as overseeing global business development, building strategic partnerships and scaling-up growth companies. He holds an MSc degree in Economics.

Jukka Tapaninen Chief Executive Officer

LinkedIn
Kaisa Helminen COO

Kaisa Helminen is the Chief Operating Officer (COO) of Aiforia. Kaisa joined Aiforia in 2014 and has previously worked for international companies Sartorius, Thermo Fisher Scientific Inc. and a Finnish biotech company Finnzymes Oy. Kaisa has a strong background in life science sector where she has gained almost 20 years of experience in the global business. She has a wealth of experience in global sales, marketing and strategic product management in life science businesses. She holds an MSc degree in Biochemistry.

Kaisa Helminen Chief Operating Officer

LinkedIn
Johan Lundin CSO

Johan is one of the co-founders of Aiforia as well as a Research Director at the Finnish Institute for Molecular Medicine (FIMM) at University of Helsinki and Professor of Medical Technology at Karolinska Institute. For more than 15 years he has developed technologies for diagnostic decision support with cloud-based and mobile solutions that allow the process to be performed remotely, by a human observer or using automated computerized analysis.

Johan Lundin, MD, PhD Chief Scientific Officer, Co-founder

LinkedIn
Mikael Lundin Director of Concept Design

Mikael works as the Director of Concept Design at Aiforia. He is a pioneer in web-based virtual microscopy and has launched the first practical applications in 2002. He has published a series of central studies in virtual microscopy together with key opinion leaders in related fields. Mikael is fluent in a wide range of programming languages, and he has a special interest in database design and imaging.

Mikael Lundin, MD Director of Concept Design, Co-founder

Kari Pitkänen Director of Business Development

Kari, M.Sc.Tech, is one of the co-founders of Aiforia. Kari is an experienced life-science entrepreneur having worked in the industry for over 30 years. He was one of the founders and Director of Marketing at Finnzymes Oy for 25 years, until its acquisition by Thermo Fisher Scientific in 2010.

Kari Pitkänen Director of Business Development, Co-founder

LinkedIn
Tuomas Ropponen CTO

Tuomas Ropponen, MSc Tech, is the Chief Technology Officer (CTO) at Aiforia. Tuomas has extensive experience in developing deep learning AI and machine vision based systems and cloud infrastructures. He has previously worked for more than 20 years in international companies Outotec and Sartorius Biohit. Tuomas was one of the founders of Delta-Enterprise, known today as Roima Intelligence Inc.

Tuomas Ropponen Chief Technology Officer

LinkedIn
Veli-Matti Parkkonen

Veli-Matti is the CFO of Aiforia and holds over 20 years experience in the financial sector in several different managerial positions. He has been involved in ECM and DCM deals, equity listings, IPOs, deal structuring and capital raisings. Veli-Matti also has been involved in venture capital and early growth companies as an investor, advisor and a board member.

Veli-Matti holds a M.Sc in Economics from University of Turku and CEFA from Hanken School of Economics.

Veli-Matti Parkkonen Chief Financial Officer

LinkedIn
Thomas Westerling-Bui, PhD

Thomas received his PhD in cancer biology, focusing on the cell cycle and transcription, from the University of Helsinki Medical School in Finland. He completed a post-doctoral EMBO fellowship at the Dana Farber Cancer Institute in Boston, researching the genomics of breast and prostate cancer. Tom joined Aiforia to advance the new potential of cancer biology, pathology, big data, and artificial intelligence.

Thomas Westerling-Bui, PhD Director, Scientific Strategy and Business Development

LinkedIn
Joeri Blauw

Joeri Blauw MSc, MBA is the Sales Director for Aiforia’s European operations. Joeri has over 20 years of commercial experience in the pharmaceutical and medical devices industries. He has worked with AstraZeneca, Roche, Medtronic and Philips, in a variety of medical specialties, ranging from cardiology to pathology. In his last assignment he was responsible for European digital pathology sales in the life sciences businesses. Joeri’s focus is to expand Aiforia’s R&D business, as well as to introduce Aiforia’s platform into the clinical diagnostics space.

Joeri Blauw European Sales Director

LinkedIn
Emma Vehviläinen Head of Marketing

Emma holds an MSc in microbiology and immunology from University College London. Prior to returning to Finland and joining Aiforia she worked in marketing and communications for a number of years across biotech and pharma, living in Cambridge, UK while working at Amgen and then Abcam.

Emma Vehviläinen Head of Marketing

LinkedIn
Sami Blom, PhD Director of Application Development

Sami’s PhD dissertation, from the University of Helsinki’s Institute for Molecular Medicine Finland (FIMM), provides novel tools for the analysis of tumor tissue in prostate cancer. From specializing in the fields of translational cancer research and in vitro diagnostics Sami’s work now extends to the development of tissue staining and imaging methods for pathology. At Aiforia Sami dedicates his time to developing AI models for a wide variety of applications while managing a large in-house annotation team.

Sami Blom, PhD Director of Application Development

LinkedIn
Juuso Juhila, PhD

Juuso holds a PhD in biomedicine from the University of Helsinki. He is an experienced Research and Development Leader having worked at Oncos Therapeutics and Medix Biochemica before joining Aiforia in 2020. Juuso has contributed to projects within pharmaceutical, biotechnological and academic research around Europe. This strong research background and encounters with various scientific fields and environments developed his skills in networking, in-vitro and molecular diagnostics, regulatory management, and IPR.

Juuso Juhila, PhD Director of Clinical Products

LinkedIn
Meet the people who support our customers

Our sales, science, and support team members

Board of Directors

Pekka Mattila Chairman of the Board

Pekka is the CEO of Desentum Oy. He holds board positions in several biotech and pharmaceutical companies. He is one of the founders of the Finnzymes Group and served as its CEO for 25 years until its acquisition by Thermo Fisher Scientific in 2010.

Pekka Mattila Chairman of the Board

LinkedIn
Monita Mo Board Member

Monita is a Hong Kong native with a professional career in Arthur Andersen NYC. She is a serial entrepreneur who has started three successful companies, including Ascend Capital Partners. She founded her own accounting firm in NYC in 1992 and her second company, Ascend Capital Partners in Beijing in 2002.

Monita Mo Board Member

LinkedIn
Johan Lundin Board Member

Johan is one of the co-founders of Aiforia as well as a Research Director at the Finnish Institute for Molecular Medicine (FIMM) at University of Helsinki and Professor of Medical Technology at Karolinska Institute.

 

Johan Lundin, MD, PhD Board Member

LinkedIn
Kari Pitkänen

Kari, M.Sc.Tech, is one of the co-founders of Aiforia. Kari is an experienced life-science entrepreneur having worked in the industry for over 30 years. He was one of the founders and Director of Marketing at Finnzymes Oy for 25 years, until its acquisition by Thermo Fisher Scientific in 2010.

Kari Pitkänen Board Member

LinkedIn

Scientific Advisory Board

Marilyn Bui, MD, PhD

Dr. Bui is a Professor of Pathology and the Scientific Director of Analytic Microscopy Core at Moffitt Cancer Center in the United States. She was the President of the Digital Pathology Association in 2019. She is recognized as an impactful leader in pathology. Dr. Bui's expertise ranges from sarcoma pathology, cytopathology, digital pathology, and cancer biomarker testing.

Marilyn Bui, MD, PhD Moffitt Cancer Center

LinkedIn
Anant Madabhushi, PhD

Dr. Madabhushi is an endowed Professor of Biomedical Engineering at Case Western Reserve University in Cleveland, Ohio in the United States and also serves as the Director of the University’s Center for Computational Imaging and Personalized Diagnostics (CCIPD). He is also a Research Scientist at the Louis Stokes Cleveland Veterans Administration (VA) Medical Center and holds an affiliate appointment at the Cleveland Clinic.

Anant Madabhushi, PhD Case Western Reserve University

LinkedIn
Yukako Yagi, PhD

Dr. Yagi is the Director of Pathology Digital Imaging at Memorial Sloan Kettering Cancer Center (MSKCC) in New York in the United States. She received her PhD from Tokyo Medical University in Japan and soon after won a Nikon Fellowship for two research years in teleradiology and pathology at Georgetown University, Washington, D.C. in the United States.

Yukako Yagi, PhD Memorial Sloan Kettering Cancer Center

LinkedIn
Jonathan Knowles, PhD

Professor Knowles is a global opinion leader in personalized medicine. He is currently a visiting Professor in Personalized Health Care at FIMM (Institute for Molecular Medicine Finland) at the University of Helsinki and a visiting Professor at the University of Oxford, UK. He also serves on the boards of a number of biotech companies and major academic centres. Most notably he was the President of Group Research for the Roche Group for 12 years until 2010 and more recently the Chairman of the Board of both Adaptimmune Ltd and Immunocore Ltd.

Jonathan Knowles, PhD Institute for Molecular Medicine Finland and University of Oxford

LinkedIn